NEKTAR THERAPEUTICS's ticker is NKTR and the CUSIP is 640268108. A total of 247 filers reported holding NEKTAR THERAPEUTICS in Q1 2022. The put-call ratio across all filers is 1.00 and the average weighting 0.0%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q4 2021 | $905,000 | -24.6% | 67,000 | 0.0% | 0.20% | -30.3% |
Q3 2021 | $1,201,000 | +4.5% | 67,000 | 0.0% | 0.29% | -4.3% |
Q2 2021 | $1,149,000 | -14.3% | 67,000 | 0.0% | 0.30% | -14.4% |
Q1 2021 | $1,340,000 | +17.6% | 67,000 | 0.0% | 0.35% | +13.8% |
Q4 2020 | $1,139,000 | +2.6% | 67,000 | 0.0% | 0.31% | -13.1% |
Q3 2020 | $1,110,000 | -26.0% | 67,000 | 0.0% | 0.36% | -28.1% |
Q2 2020 | $1,499,000 | +25.6% | 67,000 | 0.0% | 0.50% | -8.5% |
Q1 2020 | $1,193,000 | -60.5% | 67,000 | -52.1% | 0.54% | -50.0% |
Q4 2019 | $3,021,000 | +176.4% | 140,000 | +133.3% | 1.09% | +115.4% |
Q3 2019 | $1,093,000 | -48.8% | 60,000 | 0.0% | 0.50% | -36.2% |
Q2 2019 | $2,135,000 | +5.9% | 60,000 | 0.0% | 0.79% | +6.3% |
Q1 2019 | $2,016,000 | +30.2% | 60,000 | 0.0% | 0.74% | -22.5% |
Q4 2018 | $1,548,000 | -87.7% | 60,000 | -71.6% | 0.96% | -78.4% |
Q4 2017 | $12,597,000 | +794.7% | 211,000 | +251.7% | 4.44% | +723.9% |
Q1 2017 | $1,408,000 | +91.3% | 60,000 | 0.0% | 0.54% | +62.3% |
Q4 2016 | $736,000 | – | 60,000 | – | 0.33% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Camber Capital Management LP | 3,500,000 | $60,060,000 | 2.02% |
ACT CAPITAL MANAGEMENT, LLC | 161,500 | $2,772,000 | 1.42% |
Rhenman & Partners Asset Management AB | 950,000 | $16,302,000 | 1.11% |
MAVERICK CAPITAL LTD | 5,761,073 | $98,860,000 | 0.93% |
Birchview Capital, LP | 72,000 | $1,236,000 | 0.74% |
Bellevue Group AG | 4,101,404 | $70,380,000 | 0.69% |
CM Management, LLC | 50,000 | $858,000 | 0.62% |
Duquesne Family Office | 1,000,000 | $17,160,000 | 0.42% |
OSTERWEIS CAPITAL MANAGEMENT INC | 373,368 | $6,407,000 | 0.33% |
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 67,000 | $1,149,000 | 0.30% |